Dr. Joel Schuman has been named the 2027 recipient of the RPB David F. Weeks Award for Outstanding Vision Research, recognizing his pioneering contributions to ophthalmic imaging and glaucoma research that have transformed how eye diseases are diagnosed and treated worldwide. The award, which now carries $70,000 in funding (up from $50,000), celebrates researchers who have made lasting impacts on the field and, by extension, on patients' lives.

What Is Optical Coherence Tomography and Why Does It Matter?

Dr. Schuman is best known as a pioneering inventor of optical coherence tomography, commonly called OCT. This noninvasive imaging technology allows eye doctors to see detailed cross-sections of the retina and other eye structures without touching the eye or using invasive procedures. OCT has become the gold standard for diagnosing and monitoring major blinding diseases, including glaucoma, age-related macular degeneration, and diabetic retinopathy.

Before OCT, ophthalmologists had far fewer tools to quantitatively assess the internal structures of the eye. The technology fundamentally changed clinical practice by providing precise, measurable data that helps doctors catch eye diseases earlier and track how treatments are working over time. For patients, this means more accurate diagnoses and better-informed treatment decisions.

How Has Dr. Schuman Advanced Vision Science Beyond OCT?

While OCT remains his most celebrated contribution, Dr. Schuman's career spans multiple areas of vision research and innovation:

• Glaucoma Biomarkers: Dr. Schuman and colleagues were the first to identify a molecular marker for human glaucoma, a finding published in the prestigious journal Nature Medicine in 2001, opening new pathways for early detection.
• Artificial Intelligence and Machine Learning: He has continued to advance the field by applying AI and machine learning to ophthalmic imaging, helping computers learn to spot disease patterns that might escape the human eye.
• Continuous Research Funding: He has maintained continuous National Eye Institute research funding as a principal investigator since 1995 and has authored more than 450 peer-reviewed scientific journal articles.
• Leadership in Glaucoma Diagnostics: As Co-Director of the Glaucoma Service at Wills Eye Hospital and Vice Chair for Research Innovation at the Vicki and Jack Farber Vision Research Center, he continues to shape how glaucoma is understood and treated.

His work has earned international recognition through numerous honors, including the Champalimaud Vision Award, the ARVO Translational Research Award, the American Academy of Ophthalmology Lifetime Achievement Award, and the 2026 Harvey Thorpe Scroll.

What Do Colleagues Say About His Impact?

Dr. Schuman's peers consistently emphasize both the breadth and depth of his contributions to vision science. Julia A. Haller, Chief Executive Officer and Ophthalmologist-in-Chief at Wills Eye Hospital, highlighted how his work has shaped the entire field.

"Dr. Schuman's career is a testament to visionary leadership, innovative research, and tireless dedication to advancing our understanding of glaucoma pathogenesis and the development of novel diagnostic approaches. His co-invention of OCT has fundamentally changed the practice of ophthalmology and has directly benefited millions of patients worldwide," said Julia A. Haller.

Julia A. Haller, MD, Chief Executive Officer and Ophthalmologist-in-Chief at Wills Eye Hospital

Jay S. Duker, President and CEO of EyePoint, Inc., and an Adjunct Professor of Ophthalmology at Tufts Medical Center, emphasized Dr. Schuman's sustained excellence over three decades of collaboration.

"I have worked with and collaborated with Dr. Schuman for over 30 years and I can say without a doubt he is a generational talent in glaucoma research. What is really impressive is that over the subsequent 30+ years Joel has continued to be at the forefront of OCT research," stated Jay S. Duker.

Jay S. Duker, MD, President and CEO of EyePoint, Inc.

Brian F. Hofland, President of Research to Prevent Blindness, noted that the increased funding for the award reflects the organization's commitment to supporting breakthrough vision science.

"I am especially grateful to our anonymous donor for enabling us to substantially increase the amount of this award for this and future years; with this increase, we will bring additional attention to, and honor, the worthy accomplishments of groundbreaking vision scientists like Dr. Schuman and future Weeks' awardees," explained Brian F. Hofland.

Brian F. Hofland, PhD, President of Research to Prevent Blindness

What Happens Next?

Dr. Schuman will receive his award and deliver a presentation during the Association of University Professors of Ophthalmology (AUPO) 2027 Annual Meeting in Indian Wells, California. The Weeks Award, named after David F. Weeks, a former President and Chairman of Research to Prevent Blindness, has been recognizing outstanding vision researchers annually since its inception. Research to Prevent Blindness, founded in 1960 by Dr. Jules Stein, has awarded more than $440 million in research grants to vision scientists at leading medical schools and has been associated with nearly every major breakthrough in understanding and treating vision loss over the past 66 years.

Dr. Schuman's recognition underscores how foundational research in imaging technology and disease biomarkers continues to shape clinical practice and improve outcomes for millions of patients living with glaucoma, macular degeneration, and other sight-threatening conditions.